NR1H4 and primary biliary cholangitis: Accordingly, the first-in-class FXR agonist 6α-ethyl-CDCA (2, 6-ECDCA, INT-747, obeticholic acid, OCA) has gained approval for primary biliary cirrhosis (PBC) and is undergoing development for several other liver-related disorders such as NASH and NAFLD (Mudaliar et al., 2013; Neuschwander-Tetri et al., 2015).